UB-311 is a vaccine targeting β-amyloid and hence anti-amyloid agent which is under development for the treatment of Alzheimer's disease.[2][3] It is under development by Vaxxinity.[2] Meningoencephalitis has been described as a possible side effect of the drug.[4] As of February 2024, the drug is in phase 2 clinical trials.[2] In May 2022, UB-311 received fast-track designation for Alzheimer's disease from the United States Food and Drug Administration (FDA).[3]
| Vaccine description | |
|---|---|
| Target | β-Amyloid |
| Clinical data | |
| Other names | UB311 |
| Routes of administration | Intramuscular injection[1] |
References
edit- ^ Plascencia-Villa G, Perry G (2023). Lessons from antiamyloid-β immunotherapies in Alzheimer's disease. Handbook of Clinical Neurology. Vol. 193. Handb Clin Neurol. pp. 267–292. doi:10.1016/B978-0-323-85555-6.00019-9. ISBN 978-0-323-85555-6. PMID 36803816.
- ^ a b c "UB 311". AdisInsight. 5 February 2024. Retrieved 17 September 2024.
- ^ a b Zhang Y, Chen H, Li R, Sterling K, Song W (June 2023). "Amyloid β-based therapy for Alzheimer's disease: challenges, successes and future". Signal Transduct Target Ther. 8 (1): 248. doi:10.1038/s41392-023-01484-7. PMC 10310781. PMID 37386015.
- ^ Liu N, Haziyihan A, Zhao W, Chen Y, Chao H (August 2024). "Trajectory of brain-derived amyloid beta in Alzheimer's disease: where is it coming from and where is it going?". Transl Neurodegener. 13 (1): 42. doi:10.1186/s40035-024-00434-9. PMC 11331646. PMID 39160618.